Jan. 27, 2021 12:01 UTC
The Collaboration Will Leverage Innovative Technology Platforms to Help Pharma Companies Develop Drugs Faster, More Efficiently and With Higher Success Rates
IRVINE, Calif.–(BUSINESS WIRE)– GATC Health, a pioneering technology company focused on whole genome testing and Predictive Multiomics™, and Liquid Biosciences, a leader in predictive algorithms and biomarker discovery, announced an agreement to discover disease biomarkers and identify potential treatments. By linking both companies’ innovative technology platforms, the collaboration will speed the development of new prescription drugs, improve the safety and accuracy of clinical trials and lower the cost of lengthy research cycles. The companies’ shared goal is to enable clients to get effective treatments to patients sooner and at lower cost.
“This partnership will provide a more complete picture of how a disease works and potential treatments,” said Patrick Lilley, CEO at Liquid Biosciences. “By combining our Emerge mathematical evolution platform with GATC’s comprehensive biological analysis, we can identify the right biology sooner and focus on a smaller set of potential compounds early in the preclinical development process, enabling pharma companies to develop drugs with more efficiency and a higher success rate.”
The initial pipeline of diseases slated for evaluation includes a variety of neurological diseases with significant unmet needs. Liquid Bioscience’s proprietary Emerge platform, using multi-omics assays, will agnostically discover which biological processes are involved in a particular disease. This will enable GATC Health’s innovative Multiomic Advanced Technology™ (MAT) to focus on the most important biological processes and illuminate the functional biology, model potentially influenceable pathways, and identify potential treatments for the disease.
MAT is a suite of digital neural networks designed specifically to leverage omics datasets to provide insight into human biology. The proprietary platform combines advanced computerized intelligence and quantitative omics data to model biological interactions with billions of datapoints, reducing drug discovery timelines by millions of man-hours. The unique ability to illuminate functional biology across omics modalities, including genomics, gene expression, proteomics, and microbiomics, produces the most complete picture of the biology of a disease currently available. MAT results can lead to fast-tracking drug development, pre-screening clinical trial participants, identifying new drugs and repurposing existing treatments.
“Drug prices are often driven by the high level of risk and uncertainty in drug development, along with the lengthy timeline—the process may require upwards of seven million man-hours and cost billions of dollars,” said John Stroh, Interim CEO at GATC Health. “We believe that this collaboration will accelerate the process, minimize the risks, and reduce costs. We are excited for this partnership with Liquid Biosciences and for the opportunity to enhance the drug development process and improve personalized medicine.”
About GATC Health
GATC Health is a pioneering technology company using Predictive Multiomics™ to advance drug discovery and improve human health. GATC Health’s proprietary Multiomic Advanced Technology (MAT™) sequences an individual’s DNA, reading the entire genome and analyzing the full data set of omics, including genomics, proteomics, microbiomics. A complete understanding of a person’s genetics combined with the evaluation of other omics yields the most comprehensive individual health analysis available, which can lead to fast-tracking drug development, pre-screening clinical trial participants, identifying new drugs and repurposing existing treatments. GATC Health’s innovative technology takes healthcare from reactive to predictive—it is truly personalized medicine. For more information about GATC Health, visit www.GATCHealth.com.
About Liquid Biosciences
Liquid Biosciences radically reduces diagnostic and drug development risk, time, and cost, from pre-clinical research through regulatory approval. Our Emerge bio-analytics platform agnostically discovers and models the nonlinear dynamics of how biology, behavior, and circumstances interact to drive patient outcomes. Our mathematical evolution technology goes beyond artificial intelligence’s capabilities, and has produced superior accuracy, novel insights, and explainability in every head-to-head comparison with other analytic methods. Liquid Biosciences’ clients are major biopharma firms, diagnostic companies, and world-class research institutions. We’ve completed over 165 major analytic projects across 44 diseases, using the full spectrum of clinical trial, real-world, and multi-omics biomarker data. For more information about Liquid Biosciences, visit www.liquidbiosciences.com.